Latham Advises on Immutrin’s £65 Million Series A

Latham & Watkins has advised Frazier Life Sciences, Cambridge Innovation Capital, Qiming Venture Partners, and F‑Prime Capital Partners on the £65 million Series A funding round of Immutrin Ltd., a biotechnology company developing next generation antibody therapy to reverse amyloidosis.

The round was led by new investor Frazier Life Sciences, with participation from F‑Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures.

The Latham team was led by London corporate partner Shing Lo, with counsel Samantha Peacock and associate Nicole Phung. Advice was also provided on employment matters by London partner Sarah Gadd, with associate Sophie Timmins; and on data and technology matters by London partner Lydia Torne, with associate Callum Lee.